Skip to main content

Table 1 Percentage of patients with supraventricular tachycardia (SVT), ventricular tachycardia (VT) or increase in premature ventricular complexes (PCV) after receiving levosimendan or placebo

From: Effects of levosimendan on cardiac arrhythmia in patients with severe heart failure

  SVT VT Increase in PCV
Levosimendan 5% 12% 8%
Placebo 5% 15% 9%